BG Medicine, Inc. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - November 13, 2012

Attached files
FileFilename
EX-31.1 - EX-31.1 - BG Medicine, Inc.d398643dex311.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R3.htm
10-Q - FORM 10-Q - BG Medicine, Inc.d398643d10q.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R8.htm
EXCEL - IDEA: XBRL DOCUMENT - BG Medicine, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R9.htm
EX-32 - EX-32 - BG Medicine, Inc.d398643dex32.htm
EX-31.2 - EX-31.2 - BG Medicine, Inc.d398643dex312.htm
EX-10.2 - EX-10.2 - BG Medicine, Inc.d398643dex102.htm
EX-10.1 - EX-10.1 - BG Medicine, Inc.d398643dex101.htm
v2.4.0.6
Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2012
Significant Accounting Policies [Abstract]  
Summary of Inventories

Inventories at September 30, 2012 and December 31, 2011 consisted of the following:

 

                 
(in thousands)   September 30, 2012     December 31, 2011  

Raw materials

   $ 22     $ 51  

Finished goods

     430       161  
   

 

 

    

 

 

  

Total inventories

   $ 452     $ 212  
   

 

 

    

 

 

  
Summary of computation of basic and diluted net loss per share

The following table summarizes the computation of basic and diluted net loss per share applicable to common stockholders for the three and nine months ended September 30, 2012 and 2011:

 

                                 
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2012     2011     2012     2011  
    (in thousands, except share and per share data)  

Net loss

   $ (6,814 )    $ (4,881 )    $ (20,870 )    $ (12,848 ) 

Accretion of preferred stock

     —         —         —         (118 ) 
   

 

 

    

 

 

    

 

 

    

 

 

  

Net loss attributable to common stockholders

   $ (6,814 )    $ (4,881 )    $ (20,870 )    $ (12,966 ) 
   

 

 

    

 

 

    

 

 

    

 

 

  

Weighted average number of shares - basic and diluted

     20,320,190       19,344,905       20,118,768       16,925,693  

Net loss per share attributable to common stockholders - basic and diluted

   $ (0.34 )    $ (0.25 )    $ (1.04 )    $ (0.77 ) 
Common shares excluded from the computation of diluted net loss per share attributable to common stockholders

For the three and nine months ended September 30, 2012 and 2011, the following potential common shares were excluded from the computation of diluted net loss per share attributable to common stockholders because they had an antidilutive impact due to the losses reported:

 

                 
    2012     2011  

Options to purchase common stock

     2,784,777       3,202,391  

Warrants to purchase common stock

     1,086,343       1,249,001  

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by BG Medicine, Inc. and has no official or unofficial affiliation with BG Medicine, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.